Ribometrix Inc. has synthesized eukaryotic translation initiation factor 4E (eiF4E) inhibitors reported to be useful for the treatment of cancer, fibrosis, inflammatory disorders and allergy.
Scientists at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and The Xinjiang Technical Institute of Physics & Chemistry of the Chinese Academy of Sciences have disclosed NMDA receptor antagonists reported to be useful for the treatment of neurological disorders.
A collaborating team of researchers from Northwestern University and Rice University continue to build intellectual property for an implanted biohybrid (bioelectronic/engineered cell) device that has been likened to an implantable pharmacy on a chip that never runs out.
Hangzhou Glubio Therapeutics Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase protein-binding moiety covalently linked to a Wee1-like protein kinase (Wee1)-binding moiety reported to be useful for the treatment of cancer.
Chiesi Farmaceutici SpA has divulged TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis.
Sensorium Therapeutics Inc. has identified alkylated derivatives of mesembrine or mesembrenone acting as serotonin transporter (SERT) and/or phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of anxiety, depression and stress disorders.
Rome Therapeutics Inc. has synthesized 4’-halomethyl-cytidine phosphoramidate compounds acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors reported to be useful for the treatment of viral infections, cancer, inflammation, neurodegeneration and immunological disorders.
Shenzhen Borui Pharmaceutical Technology Co. Ltd. has disclosed Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of autoimmune disease, cancer and more.
Researchers from The Cleveland Clinic Foundation continue to build intellectual property to protect their invention of a portable device for regulating the flow of cerebrospinal fluid (CSF) from a patient.
Evopoint Biosciences Co. Ltd. has synthesized probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) inhibitors reported to be useful for the treatment of cancer.
RSS
